Making top-quality cancer care accessible to all.100% free, no account required.

Targeting Pain Relief with Phytocannabinoids for Cancer Survivors After Chemotherapy

NCT06731894 · Recruiting
About this trial

This study looks at how well different types of phytocannabinoids, like cannabidiol (CBD) and a mix of THC and CBD, can help reduce pain and other symptoms caused by chemotherapy in breast and colon cancer survivors. Chemotherapy can lead to a condition called peripheral neuropathy, which causes pain, tingling, and numbness. This trial hopes to see if phytocannabinoids can improve these symptoms and quality of life for patients.

Locations and contact

This trial is running at 2 locations in the United States. All of them are currently recruiting.

United States2 locations · 2 recruiting
  • City of Hope at Irvine LennarIrvine, CaliforniaRecruiting
  • City of Hope Medical CenterDuarte, CaliforniaRecruiting
Who to ask about joining
Who can join

Anyone 18 years or older can join, including men and women. Participants need to have symptoms from chemotherapy that include neuropathy. They must also be able to read and understand English. Some health conditions may prevent joining, like recent chemotherapy or certain mental health issues. The trial team will check to see if you meet these criteria.

What happens during the trial

Participants will be randomly placed into one of three groups. One group will take CBD, another will take a mix of THC and CBD, and the last group will take a placebo, which looks like the real medicine but has no active ingredients. Each group will follow a specific schedule for taking their treatment over two cycles, each lasting 28 days. All groups will also provide urine samples during the study.

The trial team

This trial is sponsored by the City of Hope Medical Center, with help from the National Cancer Institute. Dr. Richard Lee is the principal investigator leading the study.

Important dates

The trial started on October 3, 2025, and is expected to finish by January 7, 2028. It is currently enrolling new participants.

Additional information

The trial's ID is NCT06731894. It is a Phase 2 trial, which means it is looking at how well the treatments work and how safe they are. This study is regulated by the FDA and aims to include about 120 participants.

Similar trials

Other recruiting trials for the same condition, with the eligibility rules written in plain language.

Browse similar trials
Talk to a specialist

Find a top oncologist who can tell you whether a trial is a sensible option for you.

Find a doctor
Cancer hospitals

The cancer centers running studies like this one, and what each is known for.

Browse hospitals